)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Abbott Laboratories
Abbott Laboratories (ABT) investor relations material
Abbott Laboratories Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary21 Oct, 2026
Executive summary
Q3 net sales were $13.013B, up 14.5% reported and 7.0% comparable; adjusted diluted EPS rose 9.2% to $1.42.
Plans call for a tax-free distribution of the nutrition business to shareholders by end-2027, subject to approvals, following a strategic review.
Comparable sales grew across all four segments; management expects total sales growth to accelerate in 2027.
Financial highlights
Q3 GAAP net earnings fell 44.1% to $920M; adjusted net earnings rose 8.7% to $2.477B.
9M sales were $36.770B, up 11.9% reported and 5.2% comparable; adjusted net earnings rose 5.9% to $6.789B.
Adjusted gross margin was 57.2%, up 140 bps YoY; adjusted operating margin was 23.4%, up 40 bps.
Adjusted R&D was 6.9% of sales and adjusted SG&A was 26.9% of sales.
9M adjusted diluted EPS rose 6.3% to $3.88; GAAP diluted EPS was $1.67 versus $2.70.
Outlook and guidance
FY26 comparable sales growth is projected at ~6.0%; adjusted diluted EPS guidance was reaffirmed at $5.50–$5.55, with the range tightened.
Q4 adjusted diluted EPS guidance is $1.62–$1.67; Q4 FX is expected to reduce sales by ~1%.
Management expects total sales growth to accelerate in 2027, alongside EPS growth and gross-margin expansion, while taking a conservative approach to initial guidance.
Excluding nutrition’s current profile, expected sales growth acceleration is 50–100 bps, gross-margin expansion >200 bps and operating-margin expansion ~100 bps.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Abbott Laboratories
- FY sales reached $40.109B; FY2024 adjusted EPS guidance is $4.50–$4.70.ABT
Q4 2023 - Q2 2026 sales up 13% to $12.6B, adjusted EPS beats, guidance raised on diagnostics strength.ABTQ2 2026
- Q1 2026 sales up 7.8% to $11.16B, driven by Medical Devices and Exact Sciences acquisition.ABTQ1 2026
- Proxy covers director elections, auditor ratification, equity plans, and strong ESG focus.ABTProxy Filing
- Virtual annual meeting to vote on directors, auditors, compensation, and stock plans.ABTProxy Filing
- 2026 guidance targets 10% EPS growth and 7% organic sales growth, led by innovation and expansion.ABTQ4 2025
- Q3 sales up 4.9% to $10.6B, Medical Devices led growth, and adjusted EPS guidance increased.ABTQ3 2024
- Q2 sales up 4% to $10.4B, driven by double-digit Medical Devices growth and raised guidance.ABTQ2 2024
- Double-digit EPS growth and robust organic sales momentum expected to continue in 2025.ABTQ4 2024
Next Abbott Laboratories earnings date
Q4 202621 Jan, 2027
Abbott Laboratories
Next Abbott Laboratories earnings date
Q4 202621 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
The Business of Life
Abbott Laboratories is an American global and multinational healthcare company headquartered in Chicago, Illinois, and listed on the NYSE. The company is focused on manufacturing various medical devices and medications. Its products include diagnostics equipment, medical devices, nutritionals, and branded generic pharmaceuticals. Some of Abotts more well-known products include Pedialyte and FreeStyle, the latter being a monitoring system for people living with diabetes.
Sprung from a small Pharmacy
The inception of Abbott Laboratories can be traced back to 1888 when Dr. Wallace C. Abbott founded it in Chicago. Initially operating as a small pharmacy, Dr. Abbott's business focused on creating standardized drug dosages, known as "dosimetric granules", of commonly used medications. Over the decades, the company underwent significant expansion in terms of its product range and geographical outreach, transforming from its humble beginnings into a notable player in the global pharmaceutical industry.
What They Do
Abbott Laboratories offers a wide array of products and services within healthcare and nutrition. In diagnostics, it supplies tools and tests to medical facilities used in the identification of different illnesses. The company's medical devices segment manufactures equipment used in areas like cardiology, diabetes care, and neuromodulation. Additionally, they also manufacture and sell branded generic pharmaceuticals that can be purchased over the counter at pharmacies like CVS. Their portfolio of nutritional products includes products aimed both at infants and small kids, as well as adults.
Abbott Laboratories and AbbVie
In 2013, Abbott Laboratories underwent a significant transformation by spinning off its research-based pharmaceuticals division into a separate company: AbbVie. This strategic decision was aimed at allowing both companies to focus more distinctly on their respective sectors. While Abbott Laboratories retained its portfolio including medical devices, diagnostics, and nutrition, AbbVie took over the responsibility for the research-driven pharmaceutical business. This split allowed Abbott to concentrate on its extensive range of products and services, whereas AbbVie could focus on the development and commercialization of advanced therapies.